Moomoo AI 已提取核心信息
On February 13, 2024, Matsuda Masaru, associated with Arcutis Biotherapeutics, Inc. [ARQT], engaged in multiple transactions involving the acquisition of the company's common stock. The transactions, all classified under the code 'A' indicating grants, awards, or other acquisitions, resulted in a total of 119,550 shares being added to Masaru's direct holdings. The first transaction added 74,000 shares, the second 17,650 shares, and the third 27,900 shares. Following these acquisitions, Masaru's beneficial ownership of Arcutis Biotherapeutics' common stock increased to 194,184 shares. The transactions reflect a positive action status, with the shares being directly held by Masaru.
On February 13, 2024, Matsuda Masaru, associated with Arcutis Biotherapeutics, Inc. [ARQT], engaged in multiple transactions involving the acquisition of the company's common stock. The transactions, all classified under the code 'A' indicating grants, awards, or other acquisitions, resulted in a total of 119,550 shares being added to Masaru's direct holdings. The first transaction added 74,000 shares, the second 17,650 shares, and the third 27,900 shares. Following these acquisitions, Masaru's beneficial ownership of Arcutis Biotherapeutics' common stock increased to 194,184 shares. The transactions reflect a positive action status, with the shares being directly held by Masaru.
2024年2月13日，与Arcutis Biotherapeutics, Inc. [ARQT] 相关的松田胜进行了多笔涉及收购该公司普通股的交易。这些交易全部归类为 “A”，表示补助、奖励或其他收购，使Masaru的直接持股总共增加了119,550股股份。第一笔交易增加了74,000股，第二笔交易增加了17,650股，第三笔交易增加了27,900股。在这些收购之后，Masaru对Arcutis Biotherapeutics普通股的实益所有权增加到194,184股。这些交易反映了积极的行动状态，股票由Masaru直接持有。
2024年2月13日，与Arcutis Biotherapeutics, Inc. [ARQT] 相关的松田胜进行了多笔涉及收购该公司普通股的交易。这些交易全部归类为 “A”，表示补助、奖励或其他收购，使Masaru的直接持股总共增加了119,550股股份。第一笔交易增加了74,000股，第二笔交易增加了17,650股，第三笔交易增加了27,900股。在这些收购之后，Masaru对Arcutis Biotherapeutics普通股的实益所有权增加到194,184股。这些交易反映了积极的行动状态，股票由Masaru直接持有。
有用
没用